Skip to content

DBVT

DBV Technologies SA

NASDAQ · Healthcare · Biotechnology · FR

$9.59
−6.85%
Ask drillr

Year over year

Reported trailing growth

Revenue
-100.0%
EBITDA
-45.3%
EBIT
-46.2%
EPS
+43.7%
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
+58.5%
EPS
+47.5%

Three-year CAGR

Revenue
—
EBITDA
-29.6%
EBIT
-22.0%
Net income
-29.2%
EPS
-41.7%
Free cash flow
-13.4%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026